Bart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More